Global Retinal Disease Therapeutics Market – Industry Trends and Forecast to 2030

Análise e dimensão do mercado terapêutico para doenças da retina

A retina é uma delicada camada de tecido localizada na parte posterior dos olhos e é responsável pela deteção da luz e pela transferência de imagens para o cérebro. Qualquer forma de perturbação da retina pode danificar este delicado tecido e afetar a visão e, em casos graves. , levar à cegueira. Os distúrbios da retina podem ser genéticos ou relacionados com a idade, provocando alterações degenerativas na visão. Um exame da retina é, no entanto, o primeiro passo no diagnóstico da potencial doença, juntamente com testes genéticos para distúrbios genéticos da retina.

Os distúrbios da retina têm uma elevada prevalência e incidência na população geriátrica e nos doentes diabéticos, pelo que o aumento da população de doentes adultos e diabéticos irá impulsionar o mercado terapêutico para as doenças da retina.

A Data Bridge Market Research analisa que o mercado terapêutico para as doenças da retina, que foi de 12,57 mil milhões de dólares em 2022, atingiria até 25,69 mil milhões de dólares até 2030, e deverá passar por um CAGR de 9,3% durante o período de previsão. A “degeneração macular” domina o segmento das perturbações do mercado terapêutico das doenças da retina devido à maior prevalência. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito e segmentação do mercado terapêutico das doenças da retina

Definição de mercado

As doenças da retina são um grupo de condições médicas que afetam a retina, que é o tecido sensível à luz localizado na parte posterior do olho. Estas doenças podem perturbar o funcionamento normal da retina, levando à deficiência visual ou mesmo à cegueira. As doenças retinais comuns incluem a degeneração macular, a retinopatia diabética, o descolamento da retina, a retinite pigmentosa e outras. A terapêutica para as doenças da retina visa controlar e tratar estas condições para preservar ou melhorar a visão do paciente. As abordagens de tratamento podem variar consoante a doença específica e a sua gravidade, mas podem incluir medicação, terapia laser , cirurgia e dispositivos implantáveis, entre outros.

Dinâmica do mercado terapêutico para as doenças da retina

Motoristas

• Envelhecimento da população

A população idosa é mais suscetível a doenças da retina, como a degeneração macular relacionada com a idade (DMI). À medida que a população global continua a envelhecer, prevê-se que a prevalência de doenças da retina aumente, impulsionando a procura de terapêutica

• Aumento da incidência de diabetes

A retinopatia diabética é uma doença retiniana comum associada à diabetes. A crescente incidência da diabetes em todo o mundo é um impulsionador significativo do mercado terapêutico das doenças da retina

Oportunidades

• Investigação e Desenvolvimento Médico

O aumento da procura de tratamentos para as doenças da retina impulsionará os esforços de investigação e desenvolvimento. Isto apresenta oportunidades para as empresas farmacêuticas e de biotecnologia inovarem e desenvolverem novos medicamentos e terapias para as doenças da retina.

• Avanços Tecnológicos

As the market grows, there will be a greater need for advanced diagnostic and treatment technologies. This creates opportunities for companies involved in developing cutting-edge medical devices and imaging technologies for retinal diseases

Restraints/Challenges

• High Cost of Treatment

The cost of some retinal disease treatments, including anti-VEGF drugs and surgical interventions, can be prohibitively expensive. This cost burden can limit access to these therapies for some patients

• Limited Efficacy of Current Treatments

While significant progress has been made, some retinal diseases still lack highly effective treatments. For instance, advanced stages of certain diseases such as retinitis pigmentosa may have limited therapeutic options

This retinal disease therapeutics Market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Retinal disease therapeutics Market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Recent Development

• In October 2022, in a 600% million deal, Boehringer Ingelheim targets Surrozen’s preclinical disease asset. Surrozen has caught the attention of Boehringer Ingelheim, which paid the California biotech USD 12.5 million upfront for its preclinical asset designed to regenerate healthy eye tissue and potentially reverse retinal disease

Global Retinal Disease Therapeutics Market Scope

The retinal disease therapeutics Market is segmented on the basis of disorder, disorder type, treatment techniques, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disorder

• Macular Degeneration
• Diabetic Eye Disease
• Retinal Detachment
• Retinoblastoma
• Macular Pucker
• Macular Hole
• Floaters

Disorder Type

• Genetic
• Age Related

Treatment Techniques

• Laser
• Freezing
• Implanting
• Indenting
• Pneumatic Retinopexy
• Scleral Buckling
• Vitrectomy

Route of Administration

• Oral
• Topical
• Intravitreal
• Others

End-Users

• Hospitals
• Ambulatory Surgical Centers
• Home Healthcare
• Others

Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Retinal Disease Therapeutics Market Regional Analysis/Insights

The retinal disease therapeutics market is analyzed and market size insights and trends are provided by disorder, disorder type, treatment techniques, route of administration, end-users and distribution channel as referenced above.

The countries covered in the retinal disease therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America accounts for the largest market share due to the high healthcare expenditure and good quality medical facilities along with the majority of population have insurance cover to claim this type of expensive treatment.

Asia-Pacific region is expected to record the fastest growth during the forecast period due to increasing patient pool, improving public and private reimbursement infrastructure, and constant development of healthcare facilities.

 The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Retinal Disease Therapeutics Market Share Analysis

The retinal disease therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to retinal disease therapeutics market.

Some of the major players operating in the retinal disease therapeutics market are:

• Santen Pharmaceutical Co. Ltd. (Japan)
• Bausch Health Companies Inc. (Canada)
• Sentis Pharma Pvt Ltd. (India)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Johnson & Johnson Services, Inc. (U.S.)
• Novartis AG (Switzerland)
• Abbvie (U.S.)
• Regeneron Pharmaceuticals, Inc. (U.S.)
• Akorn (U.S.)
• Mitotech, SA (Russia)
• Kubota Pharmaceutical Holdings Co., Ltd. (Japan)
• GRAYBUG VISION, INC. (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Otsuka Pharmaceutical Co Ltd. (Japan)
• Senju Pharmaceutical Co., Ltd. (Japan)
• Valent Pharmaceuticals North America LLC (U.S.)
• Genentech, Inc. (U.S.)
• Ocular Therapeutix (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Kala Pharmaceuticals (U.S.)
• Eyevensys (France)
• Aldeyra Therapeutics, Inc. (U.S.)

SKU-60084